Global Retinal Disease Therapeutics Market, By Disorder (Macular Degeneration, Diabetic Eye Disease, Retinal Detachment, Retinoblastoma, Macular Pucker, Macular Hole, Floaters), Disorder Type (Genetic, Age Related), Treatment Techniques (Laser, Freezing, Implanting, Indenting, Pneumatic Retinopexy, Scleral Buckling, Vitrectomy), Route of Administration (Oral, Topical, Intravitreal, Others), End-Users (Hospitals, Ambulatory Surgical Centers, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) - Industry Trends and Forecast to 2030.
Retinal Disease Therapeutics Market Analysis and Size
The retina is a delicate layer of tissue located at the back end of the eyes and is responsible for light sensing and transferring images to brain, any form of retinal disorder may damage this delicate tissue and affect vision and in serious cases lead to blindness. Retinal disorders may be genetic or age-related, causing degenerative changes in vision. A retinal examination is however the first step in diagnosis of the potential disease along with genetic testing for genetic retinal disorders.
Retinal disorders have both high prevalence and incidence in the geriatric population and diabetic patients, therefore rise in both adult and diabetic patient population will boost the retinal disease therapeutics market.
Data Bridge Market Research analyses that the retinal disease therapeutics market which was USD 12.57 billion in 2022, would reach up to USD 25.69 billion by 2030, and is expected to undergo a CAGR of 9.3% during the forecast period. “Macular degeneration” dominates the disorder segment of the retinal disease therapeutics market owing to the higher prevalence. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Retinal Disease Therapeutics Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disorder (Macular Degeneration, Diabetic Eye Disease, Retinal Detachment, Retinoblastoma, Macular Pucker, Macular Hole, Floaters), Disorder Type (Genetic, Age Related), Treatment Techniques (Laser, Freezing, Implanting, Indenting, Pneumatic Retinopexy, Scleral (SKLAIR-ul) Buckling, Vitrectomy), Route of Administration (Oral, Topical, Intravitreal, Others), End-Users (Hospitals, Ambulatory Surgical Centers, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Santen Pharmaceutical Co. Ltd. (Japan), Bausch Health Companies Inc. (Canada), Sentis Pharma Pvt Ltd. (India), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Novartis AG (Switzerland), Abbvie (U.S.), Regeneron Pharmaceuticals, Inc. (U.S.), Akorn (U.S.), Mitotech, SA (Russia), Kubota Pharmaceutical Holdings Co., Ltd. (Japan), GRAYBUG VISION, INC. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Otsuka Pharmaceutical Co Ltd. (Japan), Senju Pharmaceutical Co., Ltd. (Japan), Valent Pharmaceuticals North America LLC (U.S.), Genentech, Inc. (U.S.), Ocular Therapeutix (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Kala Pharmaceuticals (U.S.), Eyevensys (France) and Aldeyra Therapeutics, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Retinal diseases are a group of medical conditions that affect the retina, which is the light-sensitive tissue located at the back of the eye. These diseases can disrupt the normal functioning of the retina, leading to vision impairment or even blindness. Common retinal diseases include macular degeneration, diabetic retinopathy, retinal detachment, retinitis pigmentosa, and others. Therapeutics for retinal diseases aim to manage and treat these conditions to preserve or improve a patient's vision. Treatment approaches can vary depending on the specific disease and its severity but may include medications, laser therapy, surgery, and implantable devices among others.
Retinal Disease Therapeutics Market Dynamics
Drivers
- Aging Population
The aging population is more susceptible to retinal diseases, such as age-related macular degeneration (AMD). As the global population continues to age, the prevalence of retinal diseases is expected to increase, driving the demand for therapeutics
- Rising Incidence of Diabetes
Diabetic retinopathy is a common retinal disease associated with diabetes. The increasing incidence of diabetes worldwide is a significant driver of the retinal disease therapeutics market
Opportunities
- Medical Research and Development
Increased demand for retinal disease treatments will drive research and development efforts. This presents opportunities for pharmaceutical and biotech companies to innovate and develop new drugs and therapies for retinal diseases
- Technological Advancements
As the market grows, there will be a greater need for advanced diagnostic and treatment technologies. This creates opportunities for companies involved in developing cutting-edge medical devices and imaging technologies for retinal diseases
Restraints/Challenges
- High Cost of Treatment
The cost of some retinal disease treatments, including anti-VEGF drugs and surgical interventions, can be prohibitively expensive. This cost burden can limit access to these therapies for some patients
- Limited Efficacy of Current Treatments
While significant progress has been made, some retinal diseases still lack highly effective treatments. For instance, advanced stages of certain diseases such as retinitis pigmentosa may have limited therapeutic options
This retinal disease therapeutics Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Retinal disease therapeutics Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
Recent Development
- In October 2022, in a 600% million deal, Boehringer Ingelheim targets Surrozen’s preclinical disease asset. Surrozen has caught the attention of Boehringer Ingelheim, which paid the California biotech USD 12.5 million upfront for its preclinical asset designed to regenerate healthy eye tissue and potentially reverse retinal disease
Global Retinal Disease Therapeutics Market Scope
The retinal disease therapeutics Market is segmented on the basis of disorder, disorder type, treatment techniques, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disorder
- Macular Degeneration
- Diabetic Eye Disease
- Retinal Detachment
- Retinoblastoma
- Macular Pucker
- Macular Hole
- Floaters
Disorder Type
- Genetic
- Age Related
Treatment Techniques
- Laser
- Freezing
- Implanting
- Indenting
- Pneumatic Retinopexy
- Scleral Buckling
- Vitrectomy
Route of Administration
- Oral
- Topical
- Intravitreal
- Others
End-Users
- Hospitals
- Ambulatory Surgical Centers
- Home Healthcare
- Others
Distribution Channel
- Direct Tender
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Retinal Disease Therapeutics Market Regional Analysis/Insights
The retinal disease therapeutics market is analyzed and market size insights and trends are provided by disorder, disorder type, treatment techniques, route of administration, end-users and distribution channel as referenced above.
The countries covered in the retinal disease therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America accounts for the largest market share due to the high healthcare expenditure and good quality medical facilities along with the majority of population have insurance cover to claim this type of expensive treatment.
Asia-Pacific region is expected to record the fastest growth during the forecast period due to increasing patient pool, improving public and private reimbursement infrastructure, and constant development of healthcare facilities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Retinal Disease Therapeutics Market Share Analysis
The retinal disease therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to retinal disease therapeutics market.
Some of the major players operating in the retinal disease therapeutics market are:
- Santen Pharmaceutical Co. Ltd. (Japan)
- Bausch Health Companies Inc. (Canada)
- Sentis Pharma Pvt Ltd. (India)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Johnson & Johnson Services, Inc. (U.S.)
- Novartis AG (Switzerland)
- Abbvie (U.S.)
- Regeneron Pharmaceuticals, Inc. (U.S.)
- Akorn (U.S.)
- Mitotech, SA (Russia)
- Kubota Pharmaceutical Holdings Co., Ltd. (Japan)
- GRAYBUG VISION, INC. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Otsuka Pharmaceutical Co Ltd. (Japan)
- Senju Pharmaceutical Co., Ltd. (Japan)
- Valent Pharmaceuticals North America LLC (U.S.)
- Genentech, Inc. (U.S.)
- Ocular Therapeutix (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Kala Pharmaceuticals (U.S.)
- Eyevensys (France)
- Aldeyra Therapeutics, Inc. (U.S.)
SKU-